Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This protocol has a 2-part design:
This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to
assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and
clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) with
unmethylated MGMT promoter status as adjuvant therapy following surgical resection and
initial chemoradiation with temozolomide (TMZ).